Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer (METRICS) (NCT02201381) (2022)

Government Record · Health Clinics Limited / Care Oncology Clinic (sponsor) · July 18, 2022

Health Clinics Limited / Care Oncology Clinic (sponsor), 2022-07-18: Registry record for the Care Oncology Clinic METRICS study, a non-randomized real-world trial of four metabolic medicines including mebendazole. It was withdrawn before prospective recruitment, with 0 participants enrolled.

Oral Mebendazole 100mg uid, for study duration.

n/a

Health Clinics Limited / Care Oncology Clinic (sponsor), 2022-07-18: Registry record for the Care Oncology Clinic METRICS study, a non-randomized real-world trial of four metabolic medicines including mebendazole. It was withdrawn before prospective recruitment, with 0 participants enrolled. Record field quoted from the arm description; registry record. Study type: phase 3, non-randomized, open-label, single-arm real-world trial. N=0 actual (withdrawn). Country: United Kingdom. Dose: atorvastatin up to 80 mg once daily; metformin up to 1000 mg once daily increased to twice daily; doxycycline 100 mg once daily; mebendazole 100 mg once daily. Sponsor: Health Clinics Limited (Care Oncology Clinic). Status: WITHDRAWN; reason 'Prospective recruitment not possible'; last update 2022-07-18. hasResults=false. Comparator: matched controls planned. 'Registered, no results' and withdrawn; the retrospective METRICS analysis was published separately (Agrawal et al. 2019, MBC-21). Also filed as MBD-16 (claims C1, C4).